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Abstract 
Doxorubicin (Dox) loaded thermosensitive liposomes (TSLs) have shown promising results for 
hyperthermia-induced local drug delivery to solid tumors. Typically, the tumor is heated to 
hyperthermic temperatures (41-42 °C), which induced intravascular drug release from TSLs within the 
tumor tissue leading to high local drug concentrations (1-step delivery protocol). Next to providing a 
trigger for drug release, hyperthermia (HT) has been shown to be cytotoxic to tumor tissue, to enhance 
chemosensitivity and to increase particle extravasation from the vasculature into the tumor interstitial 
space. The latter can be exploited for a 2-step delivery protocol, where HT is applied prior to i.v. TSL 
injection to enhance tumor uptake, and after 4 hours waiting time for a second time to induce drug 
release. In this study, we compare the 1- and 2-step delivery protocols and investigate which factors are 
of importance for a therapeutic response. In murine B16 melanoma and BFS-1 sarcoma cell lines, HT 
induced an enhanced Dox uptake in 2D and 3D models, resulting in enhanced chemosensitivity. In vivo, 
therapeutic efficacy studies were performed for both tumor models, showing a therapeutic response 
for only the 1-step delivery protocol. SPECT/CT imaging allowed quantification of the liposomal 
accumulation in both tumor models at physiological temperatures and after a HT treatment. A simple 
two compartment model was used to derive respective rates for liposomal uptake, washout and 
retention, showing that the B16 model has a twofold higher liposomal uptake compared to the BFS-1 
tumor. HT increases uptake and retention of liposomes in both tumors models by the same factor of 
1.66 maintaining the absolute differences between the two models. Histology showed that HT induced 
apoptosis, blood vessel integrity and interstitial structures are important factors for TSL accumulation 
in the investigated tumor types. However, modeling data indicated that the intraliposomal Dox fraction 
did not reach therapeutic relevant concentrations in the tumor tissue in a 2-step delivery protocol due to 
the leaking of the drug from its liposomal carrier providing an explanation for the observed lack of 
efficacy. 











Classical chemotherapy for treatment of solid 
tumors typically employs cytotoxic drugs with low 
molecular weight that have sizes below 1 nm. The 
latter allows the drugs to efficiently extravasate upon 
injection from the vascular compartment into the 
tumor tissue in order to reach their targets. However, 
as extravasation is not restricted to the tumor tissue, 
toxicity imposed on healthy tissues is limiting the 
therapeutic window. One approach to limit off-target 
toxicity is the encapsulation of cytotoxic drugs into 
nanoparticles, such as liposomes with sizes in the 
range of 50-200 nm, which reduces side effects 
observed for free drugs. In contrast to healthy tissues, 
tumors exhibit a poorly organized vascular system [1, 
2] with endothelial gaps [3, 4] that allow extravasation 
and accumulation of nanoparticles up to several 
hundred nanometers [1, 5]. In addition, as tumors 
often lack a functional lymphatic system, which 
impedes efficient clearance of nanoparticles, 
substantial retention of long circulating nanoparticles 
is observed [6, 7]. This enhanced permeability and 
retention (EPR) effect was first described for 
macromolecules by Matsumura and Maeda [8] and is 
a prerequisite for liposomal drug targeting. Today, 
several lipomosal drug formulations are clinically 
approved, mostly due to their improved toxicity 
profile [7]. One example is Doxil®, a long circulation 
liposomal formulation of Doxorubicin (Dox) [9, 10]. 
While liposomal encapsulation reduces off-site 
toxicity, it unfortunately reduces bioavailabity of the 
parent drug. Drug release from the liposomal carrier 
is slow as it is based on passive diffusion of the drug 
across the liposomal lipid bilayer, which strongly 
reduces peak concentrations [11]. An alternative 
approach is heat-triggered drug delivery using a drug 
that is encapsulated in the aqueous core of a 
temperature sensitive liposome (TSL), as first 
proposed by Yatvin and Weinstein [12]. A TSL retains 
the drug at body temperature, but rapidly release 
their payload at mild hyperthermic temperatures 
(40-43 °C). Heating the targeted tissue to these 
temperatures, for example using radiofrequency or 
high intensity focused ultrasound, leads to rapid 
intravascular release with subsequent substantial 
drug deposition in the tumor, which is investigated in 
numerous preclinical [13-17], yet also clinical studies 
[18, 19].  
Next to providing a trigger for drug release, 
hyperthermia (HT) exposure can induce multiple 
other changes on cellular as well as tissue level [20, 
21]. HT can cause direct cytotoxicity in vitro [22] and in 
vivo, which depends on the absolute temperature and 
exposure time, but also on the type of cell or tissue [23, 
24]. Secondly, HT can increase chemosensitivity [25, 
26] due to a synergistic effect between HT- and 
drug-induced cytotoxicity or due to an increased drug 
uptake as HT enhances cell membrane permeability 
[27, 28]. On tissue level, preclinical studies have 
shown that HT increased liposomal uptake in tumors 
[29-33]. However, clinical trials using Doxil® in 
combination with HT showed variable therapeutic 
outcomes, highlighting the clinical need for liposomal 
formulations that could more effectively release the 
drug [34, 35]. The latter inspired the design a 2-step 
drug delivery scheme, where first HT is applied to 
enhance the EPR effect followed by injection of TSLs. 
After accumulation of TSLs in the tumor, drug release 
is triggered with a second application of HT to ensure 
bioavailability of the drug. 
In a previous study, Li et al. performed a 
comparative study with Dox loaded TSL using the 
aforementioned 2-step drug delivery scheme versus a 
1-step intravascular HT-drug delivery scheme in a 
murine BLM melanoma model [36]. The conclusion of 
that study was that a 1-step treatment was more 
efficacious in treating a solid tumor than the 2-step 
approach. Here we provide a follow-up study, 
investigating 1-step and 2-step HT TSL based 
treatments in terms of in vitro cytotoxicity, drug 
uptake by cells, therapeutic efficacy and quantitative 
TSL uptake by B16 melanoma and BFS-1 sarcoma 
tumors. Furthermore, extensive ex vivo investigation 
provide data giving more insights into 
microenvironmental factors that could play a role in 
TSL accumulation for B16 and BFS-1 tumors and the 
influence of HT on these factors. 






(DSPE-PEG2000) were purchased from Lipoid 
(Ludwigshafen, Germany). DSPE-diethylenetria-
minepentaacetic acid (DTPA) was obtained from 
Avanti Polar Lipids Inc. (Alabaster, AL). 
Doxorubicin-hydrochloride solution (2 mg/ml) was 
ordered from Accord Healthcare. 4-(2-hydroxyethyl)- 
1-piperazineethanesulfonic acid (HEPES), (NH4)2SO4, 
DMEM culture medium, fetal bovine serum (FBS), 
sulforhodamine B (SRB), poly(2-hydroxyethyl-
methacrylate; HEMA), 2-Amino-2-hydroxymethyl- 




propane-1,3-diol (Tris), NaCl, glycerol, Mayer’s 
hematoxylin, eosin Y, Martius yellow, crystal scarlet 
and methyl blue were from Sigma Aldrich (St. Louis, 
MO). Nonyl phenoxypolyethoxylethanol (NP40) was 
purchased from ICN Biomedicals (Irvine, CA). 
Penicillin-streptomycin (Pen-Strep) solution was from 
Lonza (Breda, Netherlands). PD-10 desalting columns 
were bought from GE Healthcare Life Sciences 
(Buckinghamshire, UK). Entallan and rabbit-anti 
mouse Collagen IV antibody were from EMD 
Millipore (Billerica, MA). CD31 antibody (rat 
anti-mouse) was bought from Abcam (Cambridge, 
UK) and AlexaFluor 594 (goat anti-rat) and 
AlexaFluor 488 (goat anti-rabbit) from Invitrogen 
(Carlsbad, CA). Matrigel was acquired from BD (San 
Jose, CA). Cryo compound was from Klinipath 
(Duiven, Netherlands). Fluoromount-G was provided 
by Southern Biotech (Birmingham, AL). Cell death 
detection kit was obtained from Roche (Woerden, 
Netherlands). Weigert’s hematoxylin was purchased 
from Boom Chemicals (Meppel, Netherlands). 
Liposome preparation 
DPPC:DSPC:DSPE-PEG2000 at a molar ratio of 
70:25:5 were dissolved in 9:1 (vol:vol) 
chloroform/methanol. Solvent was evaporated using 
a rotary evaporator and the resulting lipid film was 
flushed under a stream of nitrogen. The lipid film was 
hydrated with a 250 mM solution of (NH4)2SO4 buffer 
pH 5.5 and extruded five times through 200 nm, 100 
nm, 80 nm and 50 nm polycarbonate membrane 
filters. A pH gradient was established using a PD-10 
column and eluting the liposomes with a pH 7.4 
HEPES buffered saline (10 mM HEPES, 135 mM 
NaCl). Phosphate concentration was determined by 
ammonium molybdate assay [37]. Dox was loaded 
into the liposomes by mixing Dox and lipid at a ratio 
of 0.15:1 (mol:mol) and incubating it for 1 h at 39°C in 
a thermoshaker. Liposomes were concentrated by 
ultracentrifugation (193000 g, 2 h, 4°C) and 
resuspended in 10 mM HEPES buffered saline pH 7.4 
yielding the final formulation of Dox-loaded TSLs 
(TSLDox). 
Radiolabeled liposome preparation 
For radiolabeled TSLs (111In-TSL), 0.1 mol% 
DSPE-DTPA was added to the formulation described 
above and produced in a similar fashion as the regular 
TSLs, with the exception that the liposomes were not 
loaded with Dox. 1 µmol TSLs was incubated with 30 
MBq 111In for 15 min at room temperature after the pH 
was set at 5.0 with 2.5 M sodium acetate. After 
incubation, labeling efficiency was determined by 
ITLC-SG (Varian Inc.) and the final volume was 
adjusted to 200 µL with HEPES buffered saline (10 
mM HEPES, 135 mM NaCl, pH 7.4). 
Cellular toxicity assay 
B16 or BFS-1 cells were seeded in 96-well plates 
and allowed to grow till 50% confluency in DMEM 
medium enriched with 10% FBS and 1% Pen-Strep. 
The medium was removed and fresh medium with a 
desired amount of free Dox or TSLDox was brought 
onto the cells and incubated according to Scheme 1. 
NT: incubation with Dox for 1 h at 37°C; HT42: 
incubation with Dox for 1 h at 42°C; HT41-NT: 
Preheating cells 1 h at 41°C, 4 h recovery at 37°C and a 
1 h incubation with Dox at 37°C; HT41-HT42: 
Preheating cells for 1 h at 41°C, 4 h recovery at 37°C 
and a 1 h incubation Dox at 42°C. For a TSLDox 
treatments on cells, 10 µM Dox was used. To apply 
HT, plates were put into a water bath set at the 
required temperature. After incubation, the Dox 
containing medium was removed and cells were 
given fresh medium for 24 h or 48 h incubation at 
37°C. Cells were fixed using 10% (w:v) trichloroacetic 
acid (TCA). After fixation, the plates were washed 
with water and 0.5% SRB solution was added to stain 
the fixed cells for 20 min. When staining was 
completed, cells were washed with 1% acetic acid and 
left to dry. 10 mM Tris was added to resuspend the 
SRB and absorbance was measured at 590 nm by 
spectrophotometry (Wallac Victor 2 Counter). 
 
 
Scheme 1. Overview of different in vitro Dox uptake treatments. Dox exposure took place at 37°C (NT) or 42°C (HT42). In two additional groups, cells were 
preheated for 1 h at 41 °C (HT41) with a 4 h recovery at 37°C before Dox uptake under NT or HT42 conditions (HT41-NT and HT41-HT42, respectively) 





Scheme 2. Overview of 1-step and 2-step treatments in vivo. For 1-step, i.v. TSLDox administration was conducted at body temperature (NT) or when the tumor was 
brought to 42 °C (HT42). 2-step treatments were composed of keeping the mouse under anesthesia at body temperature for 1 h (NT-HT42) or preheating the tumor 
at 41 °C for 1 h (HT41-HT42), prior to TSLDox injection, 4h rest and a second tumor heating at 42 °C. 
 
Cellular Doxorubicin uptake in 2D and 3D 
models 
B16 or BFS-1 cells were seeded into 75 cm2 flasks 
and grown under similar conditions as mentioned 
above until 80% confluency was reached. The cells 
were subjected to 40 µM Dox under four different 
treatment conditions as stated in Scheme 1. Exposing 
cells to elevated temperatures was done by 
submerging the 75 cm2 culture flask into a water bath. 
After incubation, the cells were washed with ice cold 
PBS, scraped from the flask and centrifuged at 200 g at 
4°C. The pellets were resuspended in 150 µL lysis 
buffer (20 mM Tris, 150 mM NaCl, 0.2% NP40, 10% 
glycerol, pH 7.4), followed by 30 min incubation on 
ice and centrifugation at 14000 g. The pellets were 
resuspended and homogenized in 500 µL PBS by brief 
probe sonication and Dox concentration was 
measured by fluorometry at 485 nm excitation and 
580 nm emission (Wallac Victor 2 Counter). Tumor 
spheroids were made according to a previously 
described method [38]. In short, conical shaped 
96-well plates were coated with poly-HEMA and 1 x 
105 cells which were centrifuged at 1000 x g for 10 min 
in the presence of 2.5% Matrigel and incubated 
overnight at 37°C. After incubation, spheroids were 
handpicked and exposed to identical treatments as in 
the 2D model in a thermoshaker (no shaking). After 
incubation, the spheroids were washed in PBS, 
embedded into Fluoromount-G and imaged by 
confocal microscopy (Zeiss LSM 510 Meta; 
Oberkochen, Germany). A 5 µm Z-stack was made 
over the surface of the spheroid to determine total 
Dox fluorescence. For each optical slice, the amount of 
saturated Dox fluorescence pixels were counted. The 
sum of saturated pixels of all tumor slices was used as 
an indicator for Dox uptake. For cryo-sectioning, 
spheroids were embedded into Cryo Compound and 
snap frozen in liquid nitrogen. 10 µm slices were 
made using a Cryostat (Leica CM1850 UV; Wetzlar, 
Germany), and afterwards embedded into 
Fluoromount-G and imaged using fluorescence 
microscopy (Zeiss Axiovert 100M; Hamamatsu 
Photonics C4742-98 camera controller). 
B16 and BFS-1 tumor generation 
Murine B16 melanoma or BFS-1 sarcoma cells (1 
x 106) were subcutaneously injected into the flank of 
C57BL6 mice (Harlan) to grow bulk tumors. After 
reaching volumes of approx. 700 mm3, animals were 
sacrificed and tumor pieces were transplanted to the 
animals of the therapeutic studies. All animal 
experiments were approved by the Erasmus MC 
animal research committee, Rotterdam, The 
Netherlands.  
Therapeutic efficacy studies in a B16 and 
BFS-1 model 
1 mm3 B16 or BFS-1 tumor pieces were 
transplanted subcutaneously onto the hind limb of 
C57BL6 mice and allowed to grow to 200 mm3 after 
which treatments were initiated as shown in Scheme 
2. NT: 1-step with 100 µL i.v. PBS injection and 1 h 
anesthesia at body temperature; HT42: 1-step with 100 
µL i.v. PBS injection and 1 h anesthesia with heated 
tumor at 42 °C; TSLDox NT: 1-step with 100 µL 5 
mg/kg TSLDox i.v. injection and 1 h anesthesia at body 
temperature; TSLDox HT42: 1-step with 100 µL 5 mg/kg 
TSLDox i.v. injection and 1 h anesthesia with heated 
tumor at 42 °C; HT41-HT42: 2-step with 1 h preheating 
tumor at 41 °C under anesthesia, 100 µL i.v. PBS 
injection, 4 h waiting period and 1 h anesthesia with 
heated tumor at 42 °C; TSLDox NT-HT42: 2-step with 1 
h anesthesia at body temperature, 100 µL 5 mg/kg 
TSLDox i.v. injection, 4 h waiting period and 1 h 
anesthesia with heated tumor at 42 °C; TSLDox 
HT41-HT42: 2-step with 1 h preheating tumor at 41°C 
under anesthesia, 100 µL 5 mg/kg TSLDox i.v. 
injection, 4 h waiting period and 1 h anesthesia with 
heated tumor at 42 °C. In the 1-step treatment 




protocol, the tumor was submerged into a 42.5 °C 
water bath for heating to 42 °C for 10 min, followed by 
an i.v. injection of TSL (5 mg/kg Dox) and further 
heating for another hour. The 2-step treatment 
procedure included heating of the tumor to 41 °C for 
one hour and an i.v. injection of TSL (5 mg/kg Dox) 10 
min after heating. Afterwards, the animal was 
allowed to rest for 4 h, followed by a second HT 
treatment for 1 h at 42 °C. In control groups 
normothermic (NT; 35 °C) conditions were used, 
where the animal was put under anesthesia for 1 h 
and kept at 35 °C on a 37 °C heating plate while 
covering the animal with tin foil. During both HT and 
NT experiments, the tumor bearing limb, with 
exception of the tumor itself, was coated in vaseline to 
prevent possible skin burns. Body temperatures of the 
mice were measured using a rectal probe. 
SPECT/CT imaging of TSL accumulation in a 
B16 and BFS-1 model 
1 x 106 cells were subcutaneously injected on the 
hind limb of C57BL6 mice and tumors were allowed 
to grow to volumes of 200 mm3. Tumors were either 
heated for one hour at 41 °C prior to injection or kept 
at 35 °C in a similar fashion as for the therapeutic 
study. 111In-TSL were i.v. injected (200 µL per mouse 
with an average activity of 33 ± 2 MBq 111In) and scans 
were made 4 h, 8 h, 24 h and 48 h after injection. Scans 
were acquired using the nanoSPECT/CT (Mediso 
Medical Imaging Systems) with the following settings 
for the SPECT scans: 20 projections, 60 seconds/ 
projection, and a quality factor of 0.8. APT1 apertures 
were used with 1.4 mm diameter pinholes (FOV 24 + 
16 mm). CT scans were acquired with 240 projections, 
45 kVp tube voltage and 500 ms exposure. Data 
analysis was performed using InVivoScope/ 
VivoQuant software (inviCRO, Boston, MA), where 
three-dimensional regions of interest were drawn 
over the tumor to calculate uptake of 111In-TSL at the 
selected time points. After the last scan, the animals 
were sacrificed and tumors and organs were 
harvested, weighed and radioactivity was determined 
using a γ-counter to calculate percentage injected dose 
per gram (%ID/g). All data were corrected for 
radioactive decay. 
Pharmacokinetic modelling: 
The blood kinetics and pharmacokinetic 
parameters of the TSLDox formulation were 
determined in an earlier study (Figure S1) [39]. 
Results from that study showed that the blood 
half-life of liposomal carrier Clip(t) can be described 
with a mono-exponential function:  
     (Eq.1) 
with Clip(0)=100%ID at time point of injection and 
t1/2,TSL = 5.6 ± 0.4 h being the circulation half-life of the 
liposomes. Upon injection, a fraction of Dox is 
instantaneous released (Burst = 8 ± 3 %) followed by a 
slow leakage of Dox from the liposomal carrier with a 
half-life of t1/2,leak = 2.7 ± 0.3 h. The concentration of 
intraliposomal dox CDox,TSL(t) can be described with 
the following equation:  
   
(Eq. 2) 
 
 The concentration of (radiolabeled) liposomes in 
the tumor, CTSL,tumor(t), can be described with a simple 
two compartment model:  
        
(Eq. 3) 
where kin, kout and kret describe the rates of uptake, 
washout and retention of TSL in the tumor 
compartment.  
Concentration of intraliposomal Dox within the 
tumor is subsequently numerically calculated 
assuming the same burst and leakage of Dox from the 
liposomal carrier as found for TSLDox in the blood 
compartment.  
Numerical integration of Eq. 3 and fitting of the 
SPECT data was performed using Mathematica® 
(version 10.2, Wolfram Research).  
Histology 
After the SPECT/CT experiments, the excised 
tumors were snap frozen in liquid nitrogen. 5 µm 
slices were cut and tumors were stained for vessels 
with an anti-CD31 antibody and AlexaFluor 594 or 
collagen with anti-collagen IV antibody and 
AlexaFluor 488. The TUNEL staining was performed 
with a cell death detection kit. The CD31 and TUNEL 
stains were quantified using ImageJ (version 1.48) 
software and by setting a manual threshold. A second 
set of frozen slices was stained with Maier’s 
hematoxylin and Eosin (H&E) or by Weigert’s 
hematoxylin, Martius yellow, crystal scarlet and 
methyl blue (MSB), followed by mounting in Entallan. 
The slices were imaged for fluorescence by confocal 
microscopy (CD31, collagen IV & TUNEL) or bright 
field microscopy (Leica DM 4000B) for H&E and MSB 
stained sections. 
Statistics 
All statistical tests were carried out using 
Graphpad Prism 5 software. All figures were 















ANOVA Bonferroni test with significant difference at 
p < 0.05. 
Results 
Preparation of TSLDox 
Loading of TSL with the formulation 
DPPC:DSPC:DSPE-PEG2000 at a molar ratio of 70:25:5 
with Dox was achieved with 100% efficacy. Dynamic 
light scattering of the resulting TSLDox indicated an 
average hydrodynamic diameter of 83 ± 3 nm and a 
zeta-potential of -7.9 ± 0.9 mV. Stability at 37 °C and 
release kinetics at 42 °C were tested in culture 
medium (10% FBS and 1% Pen-Strep) and were found 
to be similar to results obtained with 100% FBS as 
described in our previous work (Figure S2) [39]. 
Cytotoxic assays on B16 melanoma and BFS-1 
sarcoma cells 
In an in vitro study, murine B16 melanoma and 
BFS-1 sarcoma cells were exposed to various Dox 
concentrations for 1 h under the conditions depicted 
in Scheme 1. Both cell lines showed an increased 
sensitivity to Dox when the drug exposure was 
performed at hyperthermic temperatures (Figure 1). 
For B16 (Figure 1A, B) and BFS-1 (Figure 1C, D), the 
Dox sensitivity increased 8-fold. Additional 
pre-heating (HT41-HT42) did not result in a further 
increase in Dox sensitivity for B16. However, the 
18-fold increase for BFS-1 was significantly higher 
than the single HT treatment. In this case direct 
HT-induced cytotoxicity could have played a 
predominant role (Figure S3). B16 and BFS-1 cells 
were furthermore tested for survival after incubation 
with TSL (empty), 10 µM TSLDox or 10 µM free Dox 
under normothermic (NT; 37 °C) and HT42 conditions 
for 1 h. After the treatment, the cells were kept in 
culture medium for 24 h or 48 h. At 37 °C, TSLDox 
induced little toxicity to the cells, while at 42 °C the 
release of Dox was sufficient to cause high cell death 
(Figure 2). The TSL by itself had no inhibitory effect 
on cell growth, while HT did show some direct 
cytotoxicity, which was only significant for B16 24 h 
after incubation with 72 ± 11% viable cells compared 
to the NT group (Figure 2A). The addition of 10 µM 
TSLDox to a 1 h incubation with HT42 resulted in an 
immediate cytotoxic effect 24 h after the incubation 
(Figure 2A) with 25 ± 6% for B16 and 57 ± 7% cell 
survival for BFS-1. This cytotoxic effect became even 
more apparent 48 h after incubation, showing an 
almost complete cell death for both cell types (Figure 
2B). The TSLDox HT42 group showed similar results as 
where 10 µM free Dox was used (Dox HT42), 
suggesting a total Dox release from TSLDox in these 
experimental conditions. A cytotoxicity assay using a 
2-step heating protocol was not performed, as the 
main cytotoxic effect was caused by the increased 
uptake of free or released Dox during HT42. 
 
 
Figure 1. Dox cytotoxicity assay and IC50 values for B16 (A, B) and BFS-1 cells (C, D) 48h after treatment by different hyperthermia protocols. n = 3 for each data 
set. Curves were fit by non-linear regression and statistical analysis by one-way ANOVA Bonferroni test. The significance scores of all treatments versus NT groups 
are indicated with asterisks. * = p < 0.05, ** = p < 0.01, *** = p < 0.005. 
 





Figure 2. Cytotoxicity assay on B16 and BFS-1 cells 24 h (A) and 48 h (B) after a 1 h incubation with 10 µM TSLDox or free Dox under NT (37 °C) or HT42 (42 °C) 
conditions. n = 3 for each data set. Statistical analysis was carried out using one way ANOVA Bonferroni test comparing the treatment groups with the NT group 
separately at 24h and 48h. The significance scores of all treatments versus NT groups are indicated with asterisks. * = p < 0.05, ** = p < 0.01, *** = p < 0.005. 
 
In vitro Doxorubicin uptake in 2D and 3D 
models 
Next, the effect of HT on Dox uptake was 
studied in B16 and BFS-1 cells. Both cell lines 
exhibited a linear uptake of Dox over time at body 
temperature (Figure 3A,B). Incubation of both cell 
lines with Dox at HT42 significantly increased Dox 
uptake 9-fold for B16 (Figure 3A) and 6-fold for BFS-1 
cells (Figure 3B). Groups were added where the cells 
were preheated at 41 °C for 1 h followed by 4 h at 37 
°C to mimic a 2-step approach therapy. Preheating of 
the cells before incubation with Dox at NT (HT41-NT) 
or HT42 (HT41-HT42) conditions did not result in a 
significant difference compared to Dox uptake 
without preheating. Next, we used multicellular 
spheroids of BFS-1 cells to determine the Dox uptake 
as well as spatial distribution under the different 
temperature protocols in a 3D model. After 
performing similar incubation protocols as described 
before, the BFS-1 spheroids showed a similar pattern 
in Dox uptake than BFS-1 cells in the 2D standard 
culture conditions (Figure 3C, Video S1). When the 
Dox fluorescence intensity was quantified (Figure 
3D), HT42 and HT41-HT42 presented significantly more 
Dox positive areas than NT spheroids with a 6-fold 
and 10-fold increase in the summation of saturated 
Dox fluorescence pixels, respectively. HT41-NT 
treatment did not result in a significantly enhanced 
uptake. Dox did not penetrate farther than the first 
few cell layers into the spheroid, despite the heating 
protocol used (Figure 3E). B16 cells did not form 
spheroids and could therefore not be studied in the 
3D Dox uptake model. 
1-step & 2-step therapeutic study 
A therapeutic study with B16 (Figure 4A, B) and 
BFS-1 (Figure 4C, D) tumors were subjected to 1-step 
or 2-step therapies (Scheme 2). We chose 41 °C as 
preheating temperature since it has been shown that 
an intratumoral increase of TSLDox accumulation can 
be established [31] without risking significant 
vascular damage [40]. In both B16 and BFS-1 tumors, 
TSLDox with HT42 significantly outperformed all other 
treatments with an average improvement of survival 
of 7.1 ± 1.4 days for B16 and 14.6 ± 2.8 days for BFS-1 
when compared to the NT group. The body 
temperature differed significantly between NT and 
HT42 treated mice (Figure S4). Nevertheless, it 
remained at a physiological level with 35.0 ± 0.4 °C 
and 36.9 ± 1.1 °C, respectively. 
Quantitative SPECT/CT imaging of TSL 
accumulation in solid tumors 
A SPECT/CT study with 111In-TSL (labeling 
efficiency > 99%) was carried out to visualize the 
particle uptake in B16 and BFS-1 tumor bearing mice, 
comparing NT conditions versus tumor preheating 
for 1 h at 41°C prior to injection (HT41). SPECT 
imaging over time showed that the majority of the 




injected 111In-TSL were cleared by liver and spleen 
(Figure 5A, B) with tumor uptake over time. For all 
tumors, a maximum uptake was observed approx. 4 h 
post injection followed by a slight reduction over time 
leveling off at 48 h post injection. Under NT 
conditions, plateau values of 3.2 ± 0.5 and 1 ± 0.3 
%ID/cc were reached for B16 and BFS1 tumors 
respectively. Applying HT41 before injection increased 
uptake in both tumors, leading to higher maximum as 
well as plateau concentrations (B16: 6.2 ± 1.5 %ID/cc, 
BFS1: 3.3 ± 2.8 %ID/cc at 48 h p.i.) (Figure 5A-D). 
Biodistribution studies at t = 48 h p.i. were consistent 
with data derived from SPECT showing an uptake of 
111In-TSL in B16 tumors 2.8 ± 0.5 %ID/g compared to a 
considerable lower uptake of 0.9 ± 0.2 %ID/g in BFS-1 
tumors for NT experiments (Figure 5E,F). Applying 
HT41 before injection resulted in a significantly 
increased 111In-TSL accumulation measured after 48 h 
in B16 tumors (5.0 ± 1.0 %ID/g; Figure 5C, E) and 
BFS-1 tumors (2.6 ± 1.0 %ID/g; Figure 5D, F). 
SPECT data were used to fit the liposomal tumor 
uptake according to a simple two compartment 
model, deriving the rates for uptake, washout and 
retention, kin, kout, kret, in the two different tumors 
under NT and HT41 conditions (Table 1). Taking the 
earlier determined pharmacokinetic properties of the 
here used TSLDox formulation into account (Figure S1), 
the model also allowed to calculate the concentration 
of intraliposomal Dox present in the tumors as a 
function of time (Figure 5C,D). Maximum 
concentrations of intraliposomal Dox were reached 
approx. 2 hours p.i.. In contrast to the liposomal 
concentrations, intraliposomal Dox concentrations 
decreased to zero 15-20 hours p.i. due to the leakage 
from the liposomal carrier.  
 
 
Figure 3. Two-dimensional Dox uptake in B16 (A) and BFS-1 (B) cell cultures and BFS-1 spheroids (C-E). Cells or spheroids were exposed to 40 µM Dox for 1 h at 
37 °C (NT), 42 °C (HT42), or preheated at 41 °C followed by 4 h at 37 °C before a 1 h exposure to 40 µM Dox at NT (HT41-NT) or HT42 (HT41-HT42). Optical slices 
of 5 µm made by confocal microscopy of the spheroid (C) were summed up to determine the Ʃ saturated pixels (red) per spheroid (D; Video S1). Cryosections of 
10 µm (E) of the BFS-1 spheroids show spatial distribution of Dox fluorescence (red). All data sets are composed of an n = 3 experiment and compared by one way 
ANOVA Bonferroni test, * = p < 0.05, ** = p < 0.01, *** = p < 0.005. Asterisks show significance compared to NT groups. Scale bars represent 100 µm. 
 





Figure 4. Therapeutic efficacy study in C57BL6 mice with s.c. B16 or BFS-1 tumors. After treatment, results for B16 tumors were plotted for growth (A) and survival 
(B). Survival (B) was based on a size cutoff at 300% tumor size increase. Error bars in growth curve (A) represent SEM and one way ANOVA Bonferroni test was used 
to determine differences of survival in B (* = p < 0.05, ** = p < 0.01, *** = p < 0.005). Asterisks above bars show significance versus NT. BFS-1 is presented similarly 
in C and D. n = 4 for NT, TSLDox NT and HT42 groups; n = 5 for all other groups. 
 
 
The uptake as well as the retention rate of 
liposomes in B16 tumors was ca. 2 times higher 
compared to BFS-1 tumors, while washout was 
comparable for both tumors. Notably, HT41 induced 
in both tumors a comparable effect with increasing 
the kin, and kret by a factor of ca. 1.66 ± 0.13 leading to a 
more rapid and higher uptake of liposomes and 
consequently a high Dox peak concentration.  
 
Table 1: Pharmacokinetic parameters describing the tumor TSL 
uptake and retention in B16 and BFS-1 tumors. 
Tumor Condition kin / (1/h) kout / (1/h) kret / (1/h) 
B16 NT 0.0157 ± 0.004 0.39 ± 0.16 1.4 ± 0.63 
HT41 0.0233 ± 0.007 0.36 ± 0.22 2.5 ± 1.64 
BFS-1 NT 0.0074 ± 0.003 0.69 ± 0.34 0.7 ± 0.38 
HT41 0.0127 ± 0.001 0.36 ± 0.07 1.2 ± 0.24 
 
Histology 
After the SPECT-CT study, the tumors were used 
for H&E, MSB, TUNEL, CD31 and collagen IV 
staining (Figure 6 & 7). H&E staining indicated that 
B16 tumors have less strong cellular interactions as 
can be seen by the gaps in the tissue (Figure 6A), 
whereas BFS-1 has a much more compact 
morphology. Furthermore, the H&E suggests that the 
B16 tumors are more apoptotic (Figure 6A, arrows). 
Yet after HT41, apoptotic areas could be seen in both 
tumor types. MSB staining showed that B16 tumors 
have a very low presence of extracellular fibers 
(Figure 6B), whereas BFS-1 showed a more mature 
extracellular matrix (Figure 6C). Quantitative TUNEL 
staining (Figure 7A) showed high apoptosis of 14.4 ± 
10.0% for B16 when compared to BFS-1 with 0.4 ± 
0.1%. HT41 caused an increase of apoptosis, showing 
24.5 ± 13.2% for B16 and 1.2 ± 0.4% for BFS-1, which 
was a significant increase for the latter. The vessel 
staining using CD31 indicated a comparable mean 
vessel density for both tumor models (Figure 7B). The 
quantitative collagen IV staining confirmed the result 
of the MSB staining with 3.6 ± 0.3% for B16 and 14.8 ± 
1.2% mean density for BFS-1 (Figure 7C). The B16 
vessels were relatively large with collagen almost 
solely associated with the vessels (Figure 7D), 
whereas BFS-1 vessels were smaller and the 
interstitium consisted of more extracellular collagen 
matrix (Figure 7E). 
 





Figure 5. SPECT-CT study on 111In-TSL distribution in B16 (A, C, E) and BFS-1 (B, D, F) tumor bearing mice. After i.v. administration, scans were made at 4 h, 8 h, 
24 h and 48 h for all groups. B16 (A, C) and BFS-1 (B,D) tumors showed 111In-TSL accumulation after i.v. administration at NT, which could be significantly enhanced 
(unpaired two-tailed t-test; p < 0.05) by pre-heating the tumor for 1 h at 41 °C prior to 111In-TSL administration (HT41). The green line shows the 4 h time point 
where a second HT treatment would have taken place in case of a 2-step therapy. Biodistribution of 111In-TSL was done by γ-counting on excised organs and tumors 
(E, F) 48h hours after injection. Every group consisted of three animals (n = 3). 
 
Discussion 
In the field of nanomedicine, substantial research 
has been performed throughout the last decades on 
HT-triggered drug release from TSLs for treatment of 
solid tumors. In this context, mainly 1-step 
intravascular drug delivery schemes were employed, 
where tumors are heated to hyperthermic 
temperatures and drug loaded TSL are injected at the 
start of the HT treatment. In a previous study 
conducted by Li et al [36], a 2-step treatment scheme 
was investigated as a possible alternative in a BLM 
melanoma xenograft, where first HT41 is applied to 
enhance vascular permeability, then a TSLDox 
formulation was injected that subsequently 
accumulated in the tumor, followed by a second HT42 
step to release the drug from its carrier in order to 
ensure bioavailability. The aforementioned study 
showed in contrast to the 1-step therapy, that the 
2-step approach was not effective in causing a 
therapeutic response. In our experimental design we 
chose for a B16 melanoma and BFS-1 sarcoma cell line 
because tumors from these cell lines have been 
previously reported to show high and low 




EPR-mediated uptake of TSL, respectively [31]. We 
tested how these tumors respond to a 1-step versus 
2-step therapy, expanded the knowledge on how the 
tumor models responded to single versus multiple HT 
treatments in combination with local chemotherapy 
and provide extensive information on what factors 
can cause the differences in TSL accumulation 
between these tumors and which of these factors 
could be influenced by HT to increase TSL 
accumulation.  
B16 and BFS-1 cells showed a significant increase 
in Dox sensitivity when the drug exposure happened 
during HT42. The reduced IC50 with HT correlated 
with the increase Dox uptake by the cells discussed 
hereafter. Previously published data on this 
correlation showed that the outcome of these 
experiments depend on cell type and specific 
experimental conditions, e.g. exact temperature and 
duration of HT exposure [27, 41-43]. Testing TSLDox on 
these cells showed that at 37 °C the cytotoxic effect is 
minimal, whereas at 42 °C, the TSLDox released all 
drug and therefore cytotoxicity was comparable to 
free Dox. The small cytotoxic effect at 37°C could be 
caused by cellular uptake of TSLDox or by Dox leaking 
from the liposomes into culture medium (Figure S2). 
Next, we investigated the presence of a synergistic 
effect of Dox and HT for different heating schemes in 
a 2D and 3D cellular model. In a 2D model, it was 
shown that HT42 induces a faster cellular uptake of 
Dox leading to a 6-9 times higher rate of uptake in B16 
and BFS-1 cells than at 37 °C. Preheating the cells for 1 
h with HT41 followed by incubation for 4 h at 37 °C 
before adding Dox did not show any improvement of 
Dox uptake, indicating that HT-induced effects at 41 
 
 
Figure 6. 5 µm H&E stained sections of B16 and BFS-1 tumors 48 h after NT or HT41 (A). Black arrows indicate apoptotic areas. MSB stained B16 (B) and BFS-1 (C) 
with collagen stained in blue. Scale bars represent 200 µm in A and 20 µm in B and C. 
 




°C were reversible in nature and could only improve 
drug uptake during the heating and not thereafter. As 
the Dox uptake is caused by passive diffusion across 
the cell membrane, increase of cellular membrane 
fluidity and permeability during HT is the most likely 
explanation, since these effects are temporal in nature 
and fully reversible [27, 28]. Other studies have 
shown that preheating to slightly higher temperatures 
of 43-45.5 °C lead to a reduced Dox uptake most likely 
due to a more permanent and irreversible 
temperature of thermal dose induced damage [41, 44]. 
However, HT41 used for preheating in this study did 
not induce this effect as has also been reported by 
others [45]. Spheroids mimic a solid tumor in terms of 
cell physiology, presence of extracellular matrix and 
an apoptotic core [46]. For this reason, we employed 
this model to investigate whether Dox penetration 
depth into a dense structure of cells is influenced by 
different heating conditions [47, 48]. BFS-1 spheroids 
showed a similar response in Dox uptake as the 2D 
model when different HT protocols were applied. 
However, it also showed that if cells are closely 
packed, the drug does not penetrate deep into the 
structure beyond the first few layers of cells. Neither 
the spatial distribution nor the penetration depth 
could be improved by HT in tumor spheroids. A 
comparative study using B16 cells was not possible 
since B16 cells did not form spheroids. The latter 
might be caused by the lack of a substantial cell-cell 
adherence, which was also observed in ex vivo 
examination of B16 tumors described later in this 
section. 
At this stage we have only shown the potential of 
local chemotherapy and HT in vitro. However, the 
described features are only a small part of the factors 
that have to be considered for drug delivery to solid 
tumors. Therefore, we performed a therapeutic study 
as well as in vivo imaging and extensive ex vivo 
investigation on B16 and BFS-1 tumors to better 
understand the factors that could have played a role 
in various therapeutic responses. For both tumor 
types, a 1-step approach where TSLDox is i.v. 
administered during HT42 gave a significant 
therapeutic response, whereas a 2-step approach 
which relied on TSLDox accumulation in a preheated 
(HT41) tumor followed by a second HT42 step to 
induce drug release did not show a therapeutic effect. 
The SPECT/CT imaging in this case was particularly 
valuable to follow the TSL accumulation in B16 and 
BFS-1 tumors. The SPECT data were used for fitting a 
two compartment model which describes tumor 
uptake of the liposomal carrier as well as the 
intraliposomal Dox concentration in the tumor taking 
the blood kinetic and pharmacokinetic parameters of 
 
Figure 7. Quantification of cryo-section staining with TUNEL (A), CD31 (B) and collagen IV (C) was analyzed by unpaired two tailed t-test (* = p < 0.05). B16 (D) 
and BFS-1 (E) blood vessels colored red for CD31. Collagen IV stained in green. Scale bar shows 50 µm. n = 3 for all groups. 
 




TSLDox into account [39]. For both tumors and 
regardless of applying HT41 beforehand, the 
maximum concentration of liposomes was reached 
approx. 4 h p.i., when the second HT42 step was 
applied. The B16 tumors showed a significantly 
higher liposomal uptake compared to the BFS-1 tumor 
with ca. two fold higher kin and kret parameters 
reflecting a higher intrinsic EPR effect for the B16 
model. Interestingly, 1 hour of HT41 induced the same 
effect in both tumors leading to a 1.66 times increase 
in kin and kret and thus maintaining the two fold higher 
uptake of TSLs in B16 compared to BFS1 tumors.  
However, calculations suggested that maximum 
intraliposomal Dox concentrations were already 
reached 2 h p.i., and declining to zero within 20 h due 
to leakage from the TSLs. These data imply that a 
more favorable time point for the second HT42 step is 
ca. 2-3 h p.i. [36]. Based on our calculations, the 
intraliposomal Dox reached concentrations of 1.7 % 
ID/cc for B16 and 0.6 % ID/cc Dox for BFS-1 at the 
moment of the second HT42 step (i.e. after 4 h) at 
normal temperature conditions, and 3.0 % ID/cc and 
1.5 % ID/cc Dox with a preceding HT41 treatment. 
These concentrations are lower compared to typical 
values found for a 1-step delivery approach [49], 
which provides an explanation for the lack of a 
significant therapeutic response in a 2-step drug 
delivery protocol.  
Finally, we performed histological analysis of 
excised tumors and investigated factors that may 
cause the differences in TSL uptake and the 
intrinsically higher EPR effect found in B16 and BFS-1 
tumors. B16 tumors grew more aggressively than 
BFS-1, reaching volumes of 200 mm3 in 7-14 and 14-21 
days after inoculation, respectively. Especially in 
preclinical models, fast growing tumors show higher 
structural and functional abnormalities of the 
vasculature, thereby increasing the odds for a high 
EPR effect [1, 50, 51]. The mean vessel density was 
similar for B16 and BFS-1, however the morphology of 
B16 vessels appeared more tortuous and overall larger 
in size. Next to the growth rate and vascular 
properties, we also observed noticeable differences in 
cell packing and organization, which is important for 
the penetration depth of extravasated compounds 
into the tumor interstitium [47, 52, 53]. H&E staining 
showed less dense cellular packing with gaps in the 
B16 tumor tissue, whereas BFS-1 showed a higher 
density and no gaps. Therefore, the finding that BFS-1 
cells could form spheroids while B16 cells did not, 
might be indicative for cell packing and organization 
in an actual tumor. In vivo, cell packing density and 
organization is, among other reasons, depends on the 
presence of a well-defined extracellular matrix. 
Analysis on the extracellular matrix by MSB staining 
and quantitative collagen IV immunostaining showed 
that B16 tumors have an almost completely absent 
extracellular matrix, whereas BFS-1 tumors had a 
more mature extracellular matrix. These findings 
suggest that the immature interstitium of the B16 
tumor could have played a role in facilitating a higher 
EPR, confirming previously published results [54]. 
Histological analysis and quantitative TUNEL 
staining also indicated a much higher amount of 
apoptosis in the B16 tumors than in the BFS-1 tumors, 
which is typically associated with a more pronounced 
EPR effect [55, 56]. The HT41 induced increase of 
apoptosis was significant for the sectioned BFS-1 
tumors. While our study is in line with earlier 
findings showing that HT increases vascular 
permeability and promotes extravasation of 
nanoparticles [29-31], our histology data also suggest 
that substantial HT41 induced apoptosis can further 
aid EPR. 
In summary, we have shown that HT can aid in 
drug delivery by making cells more susceptible for 
Dox uptake, increasing the EPR-mediated uptake of 
liposomal drugs and by providing a trigger for drug 
release from TSLDox. All above factors play a pivotal 
role in the here employed 2-step delivery scheme. 
However, the actual amount of Dox delivered in a 
2-step approach is determined by liposomal uptake 
and stability of the formulation and can therefore 
never exceed the liposomal uptake (in %ID/g). This 
study has shown that preheated B16 and BFS-1 
tumors accumulated a maximum of 9.8 %ID/cc and 
5.0 %ID/cc of the injected TSL dose, while the 
intraliposomal Dox concentration only reached 3 and 
1.5 %ID/cc at 4 hours p.i. respectively. These Dox 
concentrations appeared insufficient to induce a 
noticeable therapeutic response. The 1-step 
intravascular drug release seems to be advantageous, 
since the injected TSLDox provide a high plasma 
concentration of Dox exposing the tumor to a high 
area under the curve over the time span of HT. 
Furthermore, the HT induced increase in Dox uptake 
by tumor cells may lead in both delivery schemes to a 
higher intracellular concentration. 
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